CClinicalTrials.gg
CompletedNCT01211860Updated Jan 10, 2014

Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

A Phase 1 interventional study of Diazoxide Choline Controlled-Release Tablet in Hypertriglyceridmia, sponsored by Essentialis, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-10.

Sponsored by Essentialis, Inc. · Phase 1 and Interventional

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Once a day oral administration with DCCR is the optimal dosing regimen

Read the detailed description

POPULATION The population will consist of generally healthy subjects with elevated fasting triglyceride levels in the range of ≥ 150 mg/dL and ≤ 1500 mg/dL at the Screening Visit.

Number of Subjects A total of 10 subjects will be enrolled in the study at 1 site in the USA.

02

Conditions studied

  • Hypertriglyceridmia

Keywords

  • DCCR
  • Diazoxide Chonline Controlled-Release Tablet = DCCR
  • Hypertriglyceridemia
  • Triglycerides
  • Pharmacokinetics
03

In context

Lead sponsor

Essentialis, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Basic requirements

  1. Healthy male and female subjects 18 to 75 years of age, inclusive at the time of dosing
  2. Body mass index (BMI) between 22 and 35 kg/m2

    Specific laboratory test results

  3. Fasting triglyceride ≥ 150 mg/dL and ≤ 1500 mg/dL
  4. Fasting glucose ≤ 110 mg/dL
  5. HbA1c ≤ 6.0 %

Exclusion criteria

Exclusion Criteria:

Medications: recent, current, anticipated

  1. Thyroid hormones or preparations within 1 month prior to Screening Visit (except in subjects on stable dose of replacement therapy for at least 1 month)
  2. Thiazide diuretics within 2 weeks prior to Screening Visit

    History of allergic reaction or significant intolerance to:

  3. Diazoxide
  4. Thiazides
  5. Sulfonamides

    Lifestyle changes

  6. Subjects intending to change exercise habits, and/or quit smoking

    Specific diagnoses, medical conditions and history

  7. Known type I or III hyperlipidemia
  8. Known type 1 DM
  9. Known type 2 DM
  10. Any other clinically significant endocrine, cardiovascular, pulmonary, neurological, psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological disease interfering with the assessments of the investigational drug, according to the Investigator

    Specific laboratory test results

  11. Any relevant biochemical abnormality interfering with the assessments of the investigational drug
05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    DCCR Treatment

    DCCR Treatment 290 mg diazoxide choline

    Drug: Diazoxide Choline Controlled-Release Tablet

Interventions

  • DrugDiazoxide Choline Controlled-Release Tablet

    DCCR 290 mg once a day for 10 days

06

What researchers measure

Primary outcomes

  1. Steady-state Pharmacokinetic profile of DCCR

    * Mean concentration-time profile for diazoxide * Steady-state pharmacokinetic parameters of diazoxide (Cmax(ss), AUC0-inf(ss), and CL/F) * Terminal elimination half-life (t½) of diazoxide

    Time frame: 10 days

Secondary outcomes

  1. Concentration-Time profile of major metabolite

    * Steady-state pharmacokinetic parameters (Cmax(ss) and AUC0-inf(ss)) of the major metabolite of diazoxide * Terminal elimination half-life (t½) of the major metabolite of diazoxide * Metabolite-to-parent ratios at steady-state in terms of Cmax(ss) and AUC0-inf(ss)

    Time frame: 10 days

07

Study locations

1 site
  • Cetero
    Fargo, North Dakota 58104, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01211860
Lead sponsor
Essentialis, Inc.
Collaborators
Cetero Research, San Antonio
Responsible party
Sponsor
First posted
Sep 30, 2010
Start date
Oct 2010
Primary completion
Nov 2010
Completion
Nov 2010
Last update
Jan 10, 2014

Study contacts

Alan K Copa, PharmD
principal investigator · Cetero Research - Fargo, ND

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion